Guidance on the use of H2 antagonists for the prevention and management of hypersensitivity

This guidance has been developed to advise healthcare professionals on the prevention and management of hypersensitivity reactions to systemic anticancer therapy in situations where H2 antagonists are in short supply or unavailable.

British Oncology Pharmacy Association